Lisa La on the Next 5 Years in Multiple Myeloma Research

Video

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed what she hopes will occur in multiple myeloma research over the next 5 years.

Transcription:

Hopefully we find a cure for myeloma. The director that I worked with at Sinai, I remember interviewing someone with him and the coordinator asked him specifically, “What is your goal in myeloma? You’re doing all these things. You've dedicated the last 20, 30 years of your life to myeloma into your patients. Your patients have your cell phone number, they call you at your house.” And he said, “To find a cure, as simple as that, why else would I dedicate my life to myeloma?”

And that resonated with me, you know, and I think that his passion and along with other oncologists that I've met along the way, who have focused on myeloma really, really have a passion and hoping to find a cure. And that's what I hope, that we are one step closer each year, and hopefully in 5 years we would have some sort of cure. But patients are living a lot longer, again, from 10 years ago when I started to now, but you know, we have to keep pushing the boundaries to see what else we can do.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content